|
| Congress Must Act |
 |
| Opinion: Rescheduling Is Recriminalizing, Descheduling Is Decriminalizing |
| President of cannabis genetics company DNA Genetics, Rezwan Khan, weighs in on Biden's cannabis policy reform plan and how rescheduling or descheduling the plant would impact the industry. More >> |
  |
| Cautious Optimism and Concern |
|
While there seems to be industry consensus that President Joe Biden’s three-step cannabis reform plan and acknowledgement that the United States’ cannabis laws have been a “failed approach” was significant, opinions diverge from there. It’s been more than a month since Biden’s announcement that he would pardon thousands of people with past simple federal cannabis possession offenses, urge governors to do the same at the state level and launch a scheduling review of cannabis’ Schedule I placement on the Controlled Substances Act, but cannabis business owners, legal experts and advisers are still grappling with the uncertainty of what rescheduling or descheduling would actually mean for state-legal cannabis markets. There is cautious optimism, and there is concern. Since the news broke, Cannabis Business Times editors have reached out to more than 20 industry stakeholders to get their take, outlining possible outcomes of how regulations would change if cannabis were rescheduled as a Schedule II through V substance or removed entirely and how cannabis cultivators and publicly traded companies are assessing the situation. CBT’s Cannabis Conference also hosted a webinar last week with a panel of experts who weighed in on how future federal decisions may impact the industry. Today’s newsletter features another perspective from Rezwan Khan, president of DNA Genetics and executive chair and president of trade association Global Alliance for Cannabis Commerce, who explains in a column why he believes “rescheduling is recriminalizing; descheduling is decriminalizing.” As the review process takes shape and more information becomes available, CBT will continue to follow this story, and we’d love to hear from you. Send me a note with your take and predictions at msimakis@gie.net. - Michelle Simakis, Editor-in-Chief |
| A New Entrepreneurial Spirit |
 |
| Cresco Labs and Columbia Care on Sean 'Diddy' Combs Deal: 'We Didn't Want To Go To Another Cannabis Operator' |
| Columbia Care CEO Nick Vita explains why he and Cresco Labs CEO and co-founder Charlie Bachtell 'weren't reliant on industry players' for the recently announced sale of some of their cannabis dispensaries and production facilities in New York, Illinois and Massachusetts, and more about what played into the decision to sell now. More >> |
 |
|
| The In-Store Showpiece |
 |
| A '360 Approach': How Airfield Supply Creates Immersive Brand Experiences |
| The California dispensary takes brand partnerships to new heights with experiential retail. More >> |
| Watch Now |
| Rescheduling or Descheduling: How Future Federal Decisions May Impact the Industry
If you missed watching this live webinar last week, we’ve got the replay available for you right now! This panel of expert industry stakeholders discuss the practical consequences of a federal crossroads—and how licensed businesses can prepare for the future. |
